Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals

J Diabetes Investig. 2016 Apr;7 Suppl 1(Suppl 1):80-6. doi: 10.1111/jdi.12446. Epub 2016 Mar 31.

Abstract

We reported that native incretins, liraglutide and dipeptidyl peptidase-4 inhibitors (DPP-4i) all confer an anti-atherosclerotic effect in apolipoprotein E-null (Apoe (-/-)) mice. We confirmed the anti-atherogenic property of incretin-related agents in the mouse wire injury model, in which the neointimal formation in the femoral artery is remarkably suppressed. Furthermore, we showed that DPP-4i substantially suppresses plaque formation in coronary arteries with a marked reduction in the accumulation of macrophages in cholesterol-fed rabbits. DPP-4i showed an anti-atherosclerotic effect in Apoe (-/-) mice mainly through the actions of glucagon-like peptide-1 and glucose-dependent insulinotropic polypepide. However, the dual incretin receptor antagonists partially attenuated the suppressive effect of DPP-4i on atherosclerosis in diabetic Apoe (-/-) mice, suggesting an incretin-independent mechanism. Exendin-4 and glucose-dependent insulinotropic polypepide elicited cyclic adenosine monophosphate generation, and suppressed the lipopolysaccharide-induced gene expression of inflammatory molecules, such as interleukin-1β, interleukin-6 and tumor necrosis factor-α, in U937 human monocytes. This suppressive effect, however, was attenuated by an inhibitor of adenylate cyclase and mimicked by 8-bromo-cyclic adenosine monophosphate or forskolin. DPP-4i substantially suppressed the lipopolysaccharide-induced expression of inflammatory cytokines without affecting cyclic adenosine monophosphate generation or cell proliferation. DPP-4i more strongly suppressed the lipopolysaccharide-induced gene expression of inflammatory molecules than incretins, most likely through inactivation of CD26. Glucagon-like peptide-1 and glucose-dependent insulinotropic polypepide suppressed oxidized low-density lipoprotein-induced macrophage foam cell formation in a receptor-dependent manner, which was associated with the downregulation of acyl-coenzyme A cholesterol acyltransferase-1 and CD36, as well as the up-regulation of adenosine triphosphate-binding cassette transporter A1. Our studies strongly suggest that incretin-related agents have favorable effects on macrophage-driven atherosclerosis in experimental animals.

Keywords: Atherosclerosis; Incretins; Vascular inflammation.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage*
  • Apolipoproteins E / genetics
  • Atherosclerosis / metabolism*
  • Coronary Restenosis / complications
  • Dipeptidyl-Peptidase IV Inhibitors / administration & dosage*
  • Disease Models, Animal
  • Foam Cells / drug effects
  • Foam Cells / metabolism
  • Gastric Inhibitory Polypeptide / metabolism*
  • Glucagon-Like Peptide 1 / metabolism*
  • Humans
  • Hyperplasia / etiology
  • Hyperplasia / metabolism
  • Incretins / administration & dosage*
  • Inflammation / metabolism*
  • Inflammation Mediators / metabolism
  • Liraglutide / administration & dosage
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Mice
  • Mice, Knockout
  • Monocytes / drug effects
  • Monocytes / metabolism

Substances

  • Anti-Inflammatory Agents
  • Apolipoproteins E
  • Dipeptidyl-Peptidase IV Inhibitors
  • Incretins
  • Inflammation Mediators
  • Gastric Inhibitory Polypeptide
  • Liraglutide
  • Glucagon-Like Peptide 1